Could NNVC Be the Next Biotech Blockbuster🤔

A Small Cap with Big Biotech Breakout Potential

April 22, 2026

*together with NanoViricides

Why NanoViricides (NNVC) Could Become the Biotech Gem That Turns a Revolutionary Broad-Spectrum Antiviral into a Multi-Billion-Dollar Market Breakthrough!

NanoViricides (NYSE: NNVC) is leveraging its proprietary nanoviricide platform to develop NV-387, a first-of-its-kind antiviral designed to neutralize viruses before they can infect human cells. 

Its mechanism, which mimics the surface of human cells, allows NV-387 to act against a wide range of pathogens including RSV, influenza, coronaviruses, measles, Mpox, and smallpox — giving NNVC a rare multi-indication potential. 

Phase I trials confirmed its safety and tolerability, while preclinical studies demonstrate remarkable efficacy, including complete cures in animal models for viruses where existing treatments fail.

With Phase II trials already underway for Mpox and FDA Orphan Drug Designation applications submitted for both Mpox and measles, NNVC is positioned for rapid regulatory advancement and first-mover advantage. 

The market opportunity spans billions in unmet needs, from seasonal flu and RSV to outbreaks of emerging viruses, making NV-387 a potentially transformative therapy. 

For investors hunting high-growth small-cap biotech plays, NNVC could represent a rare convergence of innovation, clinical validation, and market potential.

DISCLAIMER: This publication is owned and operated by Sherwood Ventures LLC (“SV”). Full disclaimer: https://bullseyealerts.com/disclaimer/.

NOT INVESTMENT ADVICE: We are a financial publisher, not a registered investment advisor. Content provided is for informational, educational, and promotional purposes only and should not be considered investment advice or a recommendation to buy or sell any security.

*PAID PROMOTION/COMPENSATION DISCLOSURE: SV has received six thousand dollars cash (via Interactive Offers) for this one day program on 4/22/26 for marketing efforts to increase public awareness of NanoViricides (NYSE: NNVC) . SV may have also previously been compensated for similar marketing efforts. As SV has received compensation from these companies, these parties have financial interests in the securities referenced. Further, SV and its affiliates may buy, sell, or hold positions in securities mentioned at any time without notice.

RISK WARNING: Investing involves substantial risk. Securities discussed may be highly speculative and volatile. Past performance is not indicative of future results, and you may lose some or all of your investment. Always consult a licensed financial professional before making investment decisions.